OBALON THERAPEUTICS, INC. (NASDAQ:OBLN) Files An 8-K Results of Operations and Financial Condition

On February 20, 2018, Obalon Therapeutics, Inc. (the “Company”) issued a press release announcing ranges of estimated changes to the Company’s previously announced preliminary, unaudited revenue for the fourth quarter and fiscal year ended December 31, 2017. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.

The information furnished with Item 2.02 of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

On February 20, 2018, the Company issued a press release announcing that the audit committee of the Company’s board of directors had completed its investigation into a purported whistleblower complaint and concluded that the allegations in the complaint are without merit.

A copy of the press release is attached to this report as Exhibit 99.1, and, except for the sixth paragraph of the press release, is incorporated herein by reference.

OBALON THERAPEUTICS INC ExhibitEX-99.1 2 pressrelease.htm EXHIBIT 99.1 Exhibit OBALON’S AUDIT COMMITTEE INVESTIGATION OF WHISTLEBLOWER ALLEGATION FINDS COMPLAINT MERITLESSSAN DIEGO,…To view the full exhibit click here
About OBALON THERAPEUTICS, INC. (NASDAQ:OBLN)
Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.